About

About company

History

CbsBioscience is committed to develop innovative diagnostic products and services that deliver high medical value to both physicians and patients.
We successfully commercialized the first clinically validated genomic test to predict the prognosis of liver cancer.

2019
MoU signed with K-MASTER Group, WHMU(Japan) and I.R.C.C.S.(Italy)
2018
Contracted with KCSG (Korean Cancer Study Group) for database construction and data analysis service
2017
Notification of non-reimbursement test for OncoHepaTest®
2016
Anti-cancer regimen clinical trial IRB approval (13 hospitals)
Eurostars2 Grant
2015
Appointed as human genome clinical translational research collaborator post-genome multi-ministry genome project R&'D Business (Ministry of Health and Welfare)
2014
Phase 2b IND approval for anti-cancer regimen including CDx Test from KFDA
Appointed to KFDA PHARM NAVI for product commercialization project
2013
OncoHepaTest® Q-Kit, OncoHepa CDx-Kit, 3rd Class Approval from KFDA
Liver cancer drug development
2011
liver cancer prognostic test contracted with domestic institutes
(Ajou University hospital, Hanyang university medical center, Samsung Medical Center, Keimyung university dongsan medical center, Asan medical center, Korea university Anam hospital, Korea university Guro hospital, Korea university Ansan hospital)
Overseas institutes (Mayo Clinic, Johns Hopkins Hospital etc.) co-research and MOU preparation
Capital increase with consideration (Korea Investment Partners Co., Ltd)
2010
Liver cancer prognostic test acquired domestic patent
MOU signed with Asan medical center in cancer biomarker development
OncoHepaTest® certified as a new Health Technology for HCC (Oct. 2010)
Ministry of Knowledge Economy appointed as main participant for “local industrial technology development project”
Initiation of the OncoHePaTest® service (Nov. 2010)
2009
Co-research with Ajou university hospital, Hanyang university hospital
Certified as Genetic Test & Testing Center
Liver cancer prognostic test patent application (domestic & worldwide)
2008
Ministry of Knowledge Economy appointed as participant for “Growth engine business”
Ministry of Knowledge Economy appointed as work package leader for “Strategic development”
Ministry of Science and Technology appointed as participant for “Excellent Research Center Project”
2007
HCC prognostic biomarker discovery & development research (SMC & POSTECH)
Commercialization of pathology expert system (Samsung Medical Center, KIST)
The Small and Medium Business Administration appointed main participant for “Leading technology innovation development business”
2006
Changed Name to CbsBioscience
Appointed as INNOBIZ company / Appointed as Military Service Alternative Enterprise
Second round development of FT-ICR MS operation system
2005
Certified as a venture company
Ministry of Commerce Industry and Energy appointed participant for "local R&D cluster establishment project"
First round development of FT-ICR MS operation system<
PINGS system acquired Korean patent
2004
Foundation of laboratory affiliated with company
Ministry of Oceans and Fisheries appointed as participant for "Fisheries specific research and development project"
2003
Foundation of CBS SOFT
Ministry of Commerce Industry and Energy appointed as main participant for "Mid-term base technology development business"